| abstract |
A process makes it possible to prepare diacetylrheine having a purity such that it is pharmaceutically usable and a residual content of undesirable aloe-emodin derivatives lower than 20 ppm in all. According to this process, the rhein-9-anthron-8-glucoside containing the aloe-emodin components is subjected to a liquid-liquid separation, the 1,8 dihydroxyanthronglucosides are oxidized until 1,8-dihydroxyanthrachinonglucoside is obtained, the remains glucosic, the 1,8-dihydroxyanthraquinone compound thus obtained is acetylated, the product thus obtained is crystallized and dried under particularly mild conditions. The invention also relates to diacetylrhein obtained by this process and to a pharmaceutical product containing this compound. |